Shu Li1, He Xu, Allan D Kirk. 1. Department of Surgery, Duke University School of Medicine, Durham, NC.
Abstract
BACKGROUND: Activation of porcine endothelial cells (PECs) is the mechanistic centerpiece of xenograft rejection. This study sought to characterize the immuno-phenotype of human T cells in response to PECs and to explore the immuno-modulation of B7 and mammalian target of rapamycin blockade of T cells and/or PECs during xeno-responses. METHODS: Rapid memory T-cell (TM) responses to PECs were assessed by an intracellular cytokine staining. T-cell proliferation to PEC with or without belatacept or rapamycin was evaluated by a mixed lymphocyte-endothelial cell reaction (MLER). Additionally, rapamycin-pretreated PECs were used in MLER. Cell phenotypes were analyzed by flow cytometry. RESULTS: Tumor necrosis factor-α/interferon-γ producers were detected in CD8+ cells stimulated by human endothelium but not PECs. MLER showed proliferation of CD4+ and CD8+ cells with predominantly memory subsets. Purified memory and naive cells proliferated following PEC stimulation with an increased frequency of TM in PEC-stimulated naive cells. Proliferating cells upregulated programmed cell death-1 (PD-1) and CD2 expression. Belatacept partially inhibited T-cell proliferation with reduced CD2 expression and frequency of the CD8+CD2highCD28- subset. Rapamycin dramatically inhibited PEC-induced T-cell proliferation, and rapamycin-preconditioned PECs failed to induce T-cell proliferation. PD-1 blockade did not restore T-cell proliferation to rapamycin-preconditioned PECs. CONCLUSIONS: Humans lack rapid TM-mediated responses to PECs but induce T-cell proliferative responses characterized largely as TM with increasing CD2 and PD-1 expression. B7-CD28 and mammalian target of rapamycin blockade of T cells exhibit dramatic inhibitory effects in altering xeno-proliferating cells. Rapamycin alters PEC xeno-immunogenicity leading to inhibition of xeno-specific T-cell proliferation independent of PD-1-PD ligand interaction.
BACKGROUND: Activation of porcine endothelial cells (PECs) is the mechanistic centerpiece of xenograft rejection. This study sought to characterize the immuno-phenotype of human T cells in response to PECs and to explore the immuno-modulation of B7 and mammalian target of rapamycin blockade of T cells and/or PECs during xeno-responses. METHODS: Rapid memory T-cell (TM) responses to PECs were assessed by an intracellular cytokine staining. T-cell proliferation to PEC with or without belatacept or rapamycin was evaluated by a mixed lymphocyte-endothelial cell reaction (MLER). Additionally, rapamycin-pretreated PECs were used in MLER. Cell phenotypes were analyzed by flow cytometry. RESULTS: Tumor necrosis factor-α/interferon-γ producers were detected in CD8+ cells stimulated by human endothelium but not PECs. MLER showed proliferation of CD4+ and CD8+ cells with predominantly memory subsets. Purified memory and naive cells proliferated following PEC stimulation with an increased frequency of TM in PEC-stimulated naive cells. Proliferating cells upregulated programmed cell death-1 (PD-1) and CD2 expression. Belatacept partially inhibited T-cell proliferation with reduced CD2 expression and frequency of the CD8+CD2highCD28- subset. Rapamycin dramatically inhibited PEC-induced T-cell proliferation, and rapamycin-preconditioned PECs failed to induce T-cell proliferation. PD-1 blockade did not restore T-cell proliferation to rapamycin-preconditioned PECs. CONCLUSIONS: Humans lack rapid TM-mediated responses to PECs but induce T-cell proliferative responses characterized largely as TM with increasing CD2 and PD-1 expression. B7-CD28 and mammalian target of rapamycin blockade of T cells exhibit dramatic inhibitory effects in altering xeno-proliferating cells. Rapamycin alters PEC xeno-immunogenicity leading to inhibition of xeno-specific T-cell proliferation independent of PD-1-PD ligand interaction.
Authors: Emanuele Cozzi; Conrad Vial; Daniel Ostlie; Bhatti Farah; Gilda Chavez; Kenneth G C Smith; John R Bradley; Sathia Thiru; Hugh F S Davies; John Wallwork; David J G White; Martin Goddard; Peter J Friend Journal: Xenotransplantation Date: 2003-07 Impact factor: 3.907
Authors: D Candinas; S Belliveau; N Koyamada; T Miyatake; P Hechenleitner; W Mark; F H Bach; W W Hancock Journal: Transplantation Date: 1996-12-27 Impact factor: 4.939
Authors: P Thompson; K Cardona; M Russell; I R Badell; V Shaffer; G Korbutt; G R Rayat; J Cano; M Song; W Jiang; E Strobert; R Rajotte; T Pearson; A D Kirk; C P Larsen Journal: Am J Transplant Date: 2011-05 Impact factor: 8.086
Authors: Chen Wang; Tai Yi; Lingfeng Qin; Roberto A Maldonado; Ulrich H von Andrian; Sanjay Kulkarni; George Tellides; Jordan S Pober Journal: J Clin Invest Date: 2013-03-08 Impact factor: 14.808
Authors: Andrew B Adams; Matthew A Williams; Thomas R Jones; Nozomu Shirasugi; Megan M Durham; Susan M Kaech; E John Wherry; Thandi Onami; J Gibson Lanier; Kenneth E Kokko; Thomas C Pearson; Rafi Ahmed; Christian P Larsen Journal: J Clin Invest Date: 2003-06 Impact factor: 14.808
Authors: J Espinosa; F Herr; G Tharp; S Bosinger; M Song; A B Farris; R George; J Cheeseman; L Stempora; R Townsend; A Durrbach; A D Kirk Journal: Am J Transplant Date: 2016-01-14 Impact factor: 8.086